LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national firm specializing in shareholder rights litigation, announces that it is investigating claims on behalf of investors in GSK plc (“GSK” or “the Company”) (NYSE : GSK) for violating securities laws.
The investigation aims to determine whether the Company has made false and/or misleading statements and/or has failed to disclose relevant information to investors. GSK’s development partner for the proposed COVID-19 treatment sotrovimab, Vir Biotechnology, Inc. (“Vir”), issued a press release on August 9, 2022, stating that the two companies “do not plan to file a biologics license application for sotrovimab”. at this time and do not intend to continue the Phase 3 COMET-STAR prophylaxis trial in the United States. Discussions with the FDA are still ongoing regarding the way forward for sotrovimab in the United States. Based on this news, the price of GSK’s US Certificate of Deposit fell more than 4.3% on August 10, 2022.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.com or by email at [email protected]
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.
Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.
This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.